Todos os estudos
RecrutamentoFASE3INTERVENCIONISTA

A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

This study is looking into a new medicine called marstacimab for young people aged 1 to 17 who have haemophilia A or B. Haemophilia is a condition where blood doesn't clot properly, leading to bleeding. The main goal is to find out if marstacimab is safe and helps prevent these bleeding episodes. Participants will receive marstacimab as a weekly injection under the skin, often at home, for 12 months. Researchers will compare their bleeding experienced during the study with their past health records to see if the medicine makes a difference. The study involves regular check-ups and phone calls over about 14 months.

Em resumo

Status
Recrutamento
Fase
FASE3
Patrocinador
Pfizer
Meta de inscrição
100
Iniciar
09 Dez 2022
Conclusão estimada
10 Sep 2028

Sobre o que é este estudo?

Haemophilia A and B are conditions where your blood doesn't clot as it should, which can lead to bleeding that is hard to stop. This often means facing painful and sometimes serious bleeding episodes. Doctors and researchers are always looking for new treatments that can make life easier and safer for people with haemophilia, especially children and teenagers.

This study is focusing on a new medicine called marstacimab. We want to understand if this medicine is safe and if it can help prevent bleeding in young people (aged 1 to 17 years old) who have haemophilia A or haemophilia B. Participants will receive marstacimab as a weekly injection under the skin, similar to a regular shot you might get at the doctor's office, but you might be able to do this at home after the first dose.

The study will follow participants for about 14 months in total. During this time, the research team will keep a close eye on their health and any bleeding episodes. They will compare these experiences to how the participants were doing before the study, to see if marstacimab helps to reduce the frequency and severity of bleeding events.

Pontos principais

  • New medicine (marstacimab) for haemophilia A or B.
  • For boys and young men aged 1 to 17.
  • Aims to reduce bleeding episodes.
  • Weekly injection, potentially at home.
  • Study lasts about 14 months with clinic visits and calls.
  • Focuses on safety and effectiveness compared to past health.

Quem pode ser elegível?

This study is open to boys and young men aged between 1 and 17 years old. They need to have a confirmed diagnosis of severe haemophilia A or moderate to severe haemophilia B. It's important that they have good health records from the past year that show their previous treatments and any bleeding episodes.

For those without 'inhibitors' (substances that can make haemophilia treatment harder), they must have been on a stable, regular preventative treatment for at least a year. If they do have inhibitors, they need to have been on a specific type of treatment for bleeding for at least a year before joining the study.

There are also weight requirements for different age groups: teenagers (12-17) must weigh at least 25 kg, and children (6-11) must weigh at least 19 kg. The minimum weight for the youngest group (1-5) will be confirmed later.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Are you a male between 1 and 17 years old?
  2. Do you have severe haemophilia A or moderate to severe haemophilia B?
  3. Do you have health records for the past year showing your treatments and bleeding?
  4. If you don't have 'inhibitors', have you been on a stable, regular preventative treatment for at least a year?
  5. If you have 'inhibitors', have you been on a specific bleeding treatment for at least a year?
  6. Do you meet the weight requirements for your age group (e.g., 25 kg for 12-17 year olds)?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you decide to take part, the study will last about 14 months. This includes an initial screening period of about a month, followed by 12 months when you’ll be receiving the study medicine, and then a month of follow-up. You will receive the study medicine, marstacimab, once a week as an injection just under the skin. The first dose will be given by the study staff, but after that, you might be able to give the weekly injections at home if you prefer and are able to. Over the 14 months, you will need to visit the study clinic at least 10 times. For some of these visits, if allowed, you might be able to have them at home instead. There will also be 6 phone calls spread out every couple of months to check in on you.

Riscos e benefícios potenciais

Taking part in this study may offer potential benefits, such as receiving a new medicine that might help reduce bleeding episodes. However, as with any medicine, there could be side effects or risks that your study doctor will discuss with you. You will be closely monitored by the study team, and you are free to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (63)

  • Intermountain - Primary Children's Hospital
    Código postal verificado
    Salt Lake City, United States· Recrutamento
  • Arbesu Hematología
    Código postal verificado
    Mendoza, Argentina· Recrutamento
  • Murdoch Children's Research Institute
    Código postal verificado
    Parkville, Austrália· Recrutamento
  • Medizinische Universität Wien
    Código postal verificado
    Viena, Áustria· Recrutamento
  • Centro Estadual de Hemoterapia e Hematologia Marcos Daniel Santos - HEMOES
    Não verificado
    Maruípe, Brazil· Ativo, mas não recrutando
  • Stollery Children's Hospital
    Código postal verificado
    Edmonton, Canada· Ativo, mas não recrutando
  • Hamilton Health Sciences - McMaster University/McMaster Children's Hospital
    Código postal verificado
    Hamilton, Canadá· Ativo, mas não recrutando
  • Beijing Children's hospital, Capital Medical University
    Código postal verificado
    Pequim, China· Recrutamento
  • Southern Medical University Nanfang Hospital
    Código postal verificado
    Guangzhou, China· Ativo, mas não recrutando
  • The Affiliated Hospital of Guizhou Medical University
    Código postal verificado
    Guiyang, China· Ativo, mas não recrutando
  • Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
    Código postal verificado
    Wuhan, China· Recrutamento
  • Tongji Hospital of Tongji Medical College of HUST/Pediatric Hematology Department Pharmacy
    Código postal verificado
    Wuhan, China· Recrutamento

Perguntas frequentes

What is haemophilia?

Haemophilia is a condition where your blood doesn't clot properly, which can lead to longer or more frequent bleeding than usual.

What is marstacimab?

Marstacimab is the new medicine being tested in this study to see if it can help prevent bleeding in people with haemophilia.

Como o medicamento é administrado?

The medicine is given as an injection once a week, just under the skin. You might be able to do this at home after the first dose.

Quanto tempo dura o estudo?

The study lasts for about 14 months in total, including screening, treatment, and follow-up.

Can girls or women join this study?

No, this study is only recruiting male participants.

Como saber mais

Pfizer CT.gov Call Center

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "A Clinical Trial of Study Medicine (Marstacimab) in Pediatri…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.